Search
The year 2020 has been marked by possibly the greatest health challenge to face modern society. The emergence of COVID-19 as a novel human pathogen
Contact us If you'd like to get in touch, please contact us by phone or email. Phone: 0400 450 240 Email: vtg@thekids.org.au The Vaccine Trials Group
CMVictory: finding a vaccine for cytomegalovirus, a serious virus for unborn babies
Māori and Pacific governance groups discuss and inform study protocols and issues that have arisen during the study, particularly those pertaining to Māori and Pacific ARF patients and their whānau.
News & Events
Nasal spray to prevent ear infections closer to fruition thanks to major grantA nasal spray that could potentially prevent childhood ear infections and reduce antibiotic use is a step closer to clinical trials thanks to a $500,000 CUREator grant.
News & Events
Trial tests which COVID-19 booster combos ‘boost’ immunityMEDIA ENQUIRIES Discover. Prevent. Cure. Mailing list Media contacts About The Kids Be Inspired Please direct general enquiries to our reception on (
News & Events
Nationwide RSV program roll-out announcedMore than two decades of research, modelling and collaboration to develop safe and effective RSV immunisations has led to a major Federal Government roll-out of a respiratory syncytial virus (RSV) immunisation program for all pregnant women and newborn babies in 2025.
News & Events
RSV rates skyrocket among Aboriginal babiesExperts are warning Aboriginal parents in Western Australia with newborn babies to be vigilant about Respiratory Syncytial Virus (RSV) as winter progresses.
Research
ATAGI 2022 Annual Statement on ImmunisationChristopher Blyth MBBS (Hons) DCH FRACP FRCPA PhD Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases; Co-Head, Infectious Diseases
Research
A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine(PNEU-PLAN)Despite widespread use of pneumococcal conjugate vaccines (PCVs) in children, morbidity and mortality caused by pneumococcal disease (PD) remain high. In addition, many children do not complete their PCV course on schedule. V114 is a 15-valent PCV that contains two epidemiologically important serotypes, 22F and 33F, in addition to the 13 serotypes present in PCV13, the licensed 13-valent PCV.